BRAF/RAS mutations and TERT promoter mutations commonly coexist to form genetic duets that drive poor clinical outcomes of PTC and hence are the main players in current genetic-based risk management of PTC (8-18) and some other cancers as well, such as melanoma (19-21). This evidence concerns the gene BRAF and cancer.